Sign in

MEDS on Nasdaq

DataMeds AI, Inc.

DataMeds AI, Inc. is an American wholesale-drugs company, incorporated in Delaware.1 It is headquartered in Tampa, Florida.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Cellyan Biotechnology Co., Ltd, Cosmos Health Inc. or Stemtech Corp, or pick any stock.

  • TickerMEDS on Nasdaq1
  • IndustryWholesale-Drugs, Proprietaries & Druggists' Sundries1
  • HeadquartersTampa, Florida1
  • Incorporated inDE2
  • Business address3000 Bayport Drive Suite 950, Tampa, Fl 336072
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

31, 2024, and to provide for the Company to extend such date for a maximum of ninety days, among other things.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-27.5%Gross margin4
-401.7%Operating margin4
-433.9%Net margin4
28.7%Revenue growth, 20254

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue100¢$29.8M

Out of $23.3M in revenue.4 The company lost money this year.

Financial statements

Revenue4$23.3M in 2025+29% since 2024
0$10.0M$20.0M$30.0M2024: $18.1M$18.1M20242025: $23.3M$23.3M2025+29%
Gross profit4-$6.4M in 2025
-$7.5M-$5.0M-$2.5M0$2.5M2024: $1.8M$1.8M20242025: -$6.4M-$6.4M2025
Operating income54-$93.7M in 2025+3154% since 2023
-$100.0M-$75.0M-$50.0M-$25.0M02023: -$2.9M-$2.9M20232024: -$6.1M-$6.1M2024+113%2025: -$93.7M-$93.7M2025+1426%
Net income54-$101.3M in 2025+3397% since 2023
-$150.0M-$100.0M-$50.0M02023: -$2.9M-$2.9M20232024: -$6.9M-$6.9M2024+137%2025: -$101.3M-$101.3M2025+1377%
Fiscal year2022202320242025
Revenue$18.1M4$23.3M4
Cost of revenue$16.4M4$29.8M4
Gross profit$1.8M4-$6.4M4
Operating expenses$2.9M5$7.9M4$87.3M4
Operating income-$2.9M5-$6.1M4-$93.7M4
Income before tax-$2.9M5-$6.9M4-$101.3M4
Net income-$2.9M5-$6.9M4-$101.3M4
Earnings per share-$0.065-$0.154-$1.434
Earnings per share (diluted)-$0.065-$0.154-$1.434
Shares (weighted, basic)44.7M shares547.3M shares471.0M shares4
Shares (weighted, diluted)44.7M shares547.3M shares471.0M shares4

Compare DataMeds AI, Inc. with another company

What it owns

What DataMeds AI, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$589.2K4 Dec 31, 2025$589.2K4 Dec 31, 20240%
Furniture and fixtures$152.2K4 Dec 31, 2025$152.2K4 Dec 31, 20240%
Computer equipment and software$2.5M4 Dec 31, 2025$1.6M4 Dec 31, 2024+54.5%
Leasehold improvements$766.5K4 Dec 31, 2025$766.5K4 Dec 31, 20240%
Property and equipment, before depreciation$1.5M4 Dec 31, 2025$1.5M4 Dec 31, 20240%
Accumulated depreciation$1.3M4 Dec 31, 2025$1.1M4 Dec 31, 2024+14.2%
Property and equipment, net$229.4K4 Dec 31, 2025$388.2K4 Dec 31, 2024−40.9%
Operating-lease assets (leased space)$966.9K4 Dec 31, 2025$1.5M4 Dec 31, 2024−36.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$42.6K4 Dec 31, 2025$1.0M4 Dec 31, 2024−95.9%
Stakes in other companies (equity method)$17.7K5 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$14.2M4 Dec 31, 2025$16.2M4 Dec 31, 2024−12.5%
Intangible assets, net (excluding goodwill)$2.5M4 Dec 31, 2025$1.6M4 Dec 31, 2024+54.5%
Finite-lived intangibles, gross$24.3M4 Dec 31, 2025$21.8M4 Dec 31, 2024+11.5%
Accumulated amortization$4.1M4 Dec 31, 2025$1.0M4 Dec 31, 2024+291.5%
Finite-lived intangibles, net$10.3M4 Dec 31, 2025$20.7M4 Dec 31, 2024−50.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.6M4 Dec 31, 2025$9.5M4 Dec 31, 2024−82.8%
Finished goods$2.1M4 Dec 31, 2025$3.0M4 Dec 31, 2024−31.7%

Properties, in its own words

We do not own any real property. We entered into a lease for our current corporate office space at 3000 Bayport Drive, Suite 950, Tampa, Florida 33607 in May 2024. The lease included a 3-year term, beginning May 2024, and ending June 2027. The office space occupies approximately 6,200 square feet. The Company holds a 60% share in this lease, with Wellgistics, LLC holding the remaining 40%. The lease includes a monthly base rent of $18,792. The lease required a security deposit by the Company of $35,855 and Wellgistics, LLC of $31,871.

We believe our current and future facilities are adequate for our current and near-term needs. Additional space may be required as we expand our activities. We do not currently foresee any significant difficulties in obtaining any required additional facilities.

Item 2 of the 10-K filed Mar 20, 2026.3

Leadership

Who has led DataMeds AI, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Brian Norton2025–now

Chief financial officer

  1. Mark Disiena2025–now
Board members and other officers (14)

Former names

  • Wellgistics Health, Inc.Aug 1, 2024 to Jul 21, 20262
  • Danam Health, IncJul 22, 2024 to Sep 27, 20242

Timeline

  1. Oct 13, 20268-K Other events24
  2. Sep 17, 20268-K Other events25
  3. Sep 16, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares26
  4. Aug 18, 20268-K Results of operations27
  5. Aug 14, 20268-K Other events28
  6. Aug 4, 20268-K Entered a material agreement29
  7. Jul 29, 20268-K Other events30
  8. Jul 21, 20268-K Bylaws or fiscal year changed; Other events31
  9. Jun 12, 20268-K Listing notice or transfer; Other events32
  10. Jun 3, 20268-K Financial statements and exhibits33
  11. Jun 2, 20268-K Financial statements and exhibits34
  12. May 29, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure35
  13. Mar 12, 2025New chief executive Brian Norton becomes CEO8

Calendar

Coming up

  1. Nov 18, 2026Reports results for the quarter ending Sep/202636

When it reported results

  1. Aug 18, 2026Reported quarterly or annual results27
  2. May 19, 2026Reported quarterly or annual results37
  3. Nov 20, 2025Reported quarterly or annual results38
  4. Aug 22, 2025Reported quarterly or annual results39

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

172 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 61 major events, 32 insider forms, 71 other. The latest 20:

  1. Oct 13, 20268-K EDGAR
  2. Oct 9, 2026PRE 14C EDGAR
  3. Oct 9, 2026S-1/A EDGAR
  4. Sep 17, 20268-K EDGAR
  5. Sep 16, 20268-K EDGAR
  6. Aug 31, 2026PRE 14C EDGAR
  7. Aug 18, 20268-K EDGAR
  8. Aug 17, 202610-Q EDGAR
  9. Aug 14, 20268-K EDGAR
  10. Aug 14, 2026NT 10-Q EDGAR
  11. Aug 7, 2026S-1 EDGAR
  12. Aug 4, 20268-K EDGAR
  13. Jul 29, 20268-K EDGAR
  14. Jul 21, 20268-K EDGAR
  15. Jun 25, 20264 EDGAR
  16. Jun 25, 20264 EDGAR
  17. Jun 25, 20264/A EDGAR
  18. Jun 25, 20264/A EDGAR
  19. Jun 18, 2026PRE 14A EDGAR
  20. Jun 12, 20268-K EDGAR

The 172 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jane Street Group, LLC20,532$63.6K0.0%New
Geode Capital Management, LLC12,467$38.6K0.0%New
Vanguard Capital Management LLC11,085$34.4K0.0%New
Vanguard Fiduciary Trust Co6,191$19.2K0.0%New
Barclays PLC723$2.2K0.0%New
Tower Research Capital LLC (TRC)678$2.1K0.0%New
Fortitude Family Office, LLC118$3660.0%New
Integrated Wealth Concepts LLC25$780.0%New
Global Retirement Partners, LLC2$60.0%New
Danske Bank A/s1$30.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How DataMeds AI, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDataMeds AI, Inc.1
  • CIK0002030763
  • Employer ID (EIN)93-32642343
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business address3000 Bayport Drive Suite 950, Tampa, FL 336071
  • Phone1-843-302-17851
  • Shares outstanding3,061,919 as of Aug 17, 20267
  • Public float$27.1M as of Jun 30, 20253
  • AuditorSuri & Co., Chartered Accountants, Bengaluru, India PCAOB ID 6727; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJul 22, 20241
  • Filings172 in all: 8-K (56), 3 (17), CORRESP (14), 4 (13), S-1/A (11), UPLOAD (11), 10-Q (5), 8-K/A (5)1
    All 29 form types

    EFFECT (4), NT 10-Q (4), PRE 14C (4), S-1 (4), 10-K (2), 4/A (2), 424B3 (2), 424B4 (2), DEF 14C (2), DRS (2), PRE 14A (2), 10-K/A (1), 8-A12B (1), CERT (1), DEF 14A (1), DRS/A (1), DRSLTR (1), FWP (1), PRER14A (1), PRER14C (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 20, 2026
    Quarterly report (10-Q) Aug 17, 2026
    Proxy statement (DEF 14A) May 4, 2026
    Latest 8-K (8-K) Oct 13, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 Par Value Per ShareWGRXNASDAQ

From the cover page of the 10-K filed Mar 20, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks DataMeds AI, Inc. names in Item 1A of its 10-K filed Mar 20, 2026: 65 risks under these headings, as written.3

  • Risks Related to Our Business
  • Our limited operating history as a combined company and our evolving business make it difficult to evaluate our current business and future prospects and increase the risk of your investment.
  • Wellgistics Health may experience difficulties in integrating the operations of Wellgistics LLC and Wood Sage thereby hindering Wellgistics Health from realizing the expected benefits of these transactions.
  • Reductions in third-party reimbursement levels, from private or governmental agency plans, and potential changes in industry pricing benchmarks for prescription drugs could materially and adversely affect Wellgistics Health’s results of operations.
  • A shift in pharmacy mix toward lower margin plans, margin compression on branded medications, increased offering of specialty products, DIR fees, mail order pharmacy steering, and programs could adversely affect Wellgistics Health’s results of operations.
  • Wellgistics Health will derive a portion of its sales from prescription drug sales reimbursed by PBM companies and Wellgistics Health’s participation in the pharmacy provider networks of these companies may be restricted or terminated.
  • Wellgistics Health could be adversely affected by a decrease in the introduction of new brand name and generic prescription drugs as well as increases in the cost to procure prescription drugs.
  • Consolidation and strategic alliances in the healthcare industry could adversely affect Wellgistics Health’s business operations, competitive positioning, financial condition and results of operations.
  • Changes in economic conditions could adversely affect consumer/client buying practices and market adoption of Wellgistics Health’s DelivMeds mobile application and the accompanying revenues to premium access/services.
  • Inflationary pressures could have a material impact on Wellgistics Health’s business and operations.
  • The industries in which Wellgistics Health will operate are highly competitive and constantly evolving and changes in market dynamics could adversely impact us.
  • If Wellgistics Health does not successfully create and implement relevant omni-channel experiences for Wellgistics Health’s customers, Wellgistics Health’s businesses and results of operations could be adversely impacted.
The other 54 risks
  • Wellgistics Health may be unable to achieve Wellgistics Health’s environmental, social and governance goals.
  • Wellgistics Health’s business results will depend on Wellgistics Health’s ability to successfully manage ongoing organizational change and business transformation and achieve cost savings and operating efficiency initiatives through Wellgistics Health’s healthcare ecosystem.
  • Our common stock is subject to a Nasdaq minimum bid price deficiency notice, and failure to regain compliance could result in the delisting of our common stock from The Nasdaq Capital Market.
  • We are involved in litigation with former management relating to equity awards, and the outcome of this matter could adversely affect our financial condition.
  • Risks Relating to Wellgistics Health’s Operations
  • Disruption in Wellgistics Health’s global supply chain could negatively impact Wellgistics Health’s businesses.
  • Wellgistics Health’s business and operations will be subject to risks related to climate change.
  • Wellgistics Health’s business is primarily focused on certain therapeutic targets, making it vulnerable to risks associated with having therapeutically concentrated operations.
  • Failure to retain and recruit, or failure to manage succession of, key personnel could have an adverse impact on Wellgistics Health’s future performance.
  • We are highly dependent on the continued service of our directors and officers, whose financial interests may conflict with the interests of investors.
  • Failure to renew facility leases in a timely manner could have an adverse impact on Wellgistics Health’s business operations.
  • Wellgistics Health may not be able to maintain business, scale for growth, renew pharmacy and wholesale state licenses, and retain commercial and federal contracts while preventing restrictions and termination.
  • Wellgistics Health’s relationships with Wellgistics Health’s primary wholesaler for pharmacy operations and Wellgistics Health’s manufacturer relationships for Wellgistics Health’s wholesale and hub technology platform entities will be critical to Wellgistics Health’s success.
  • Wellgistics Health will outsource certain business processes to third-party vendors that subject us to risks, including disruptions in business and increased costs.
  • Risks Relating to Wellgistics Health’s Business Strategy
  • Wellgistics Health may not be successful in executing elements of Wellgistics Health’s business strategy, which may have a material adverse impact on Wellgistics Health’s business and financial results.
  • Wellgistics Health’s growth strategy is partially dependent upon Wellgistics Health’s ability to identify and successfully complete acquisitions, joint ventures and other strategic partnerships and alliances.
  • Businesses acquired by Wellgistics Health could experience losses or liabilities that would result in a material adverse effect on Wellgistics Health’s business operations, results of operation and financial condition.
  • Wellgistics Health may make investments in companies over which Wellgistics Health does not have sole control and some of these companies may operate in sectors that differ from Wellgistics Health’s operations and have different risks.
  • The success of Wellgistics Health’s hub technology platform and clinical services depends on the willingness of participants in the network of independent partner pharmacies to continue receiving prescriptions and enrolling in a-la-carte services for outsourced work.
  • Risks Related to Cybersecurity, Data Privacy, and Information Security
  • A significant disruption in Wellgistics Health’s information technology and computer systems or those of businesses Wellgistics Health relies on could harm Wellgistics Health.
  • Privacy and data protection laws will increase Wellgistics Health’s compliance burden and any failure to comply could harm Wellgistics Health.
  • Wellgistics Health and businesses with which Wellgistics Health will interact may experience cybersecurity incidents and might experience significant computer system compromises or data breaches.
  • Wellgistics Health will be subject to electronic payment-related and other financial services risks that could increase Wellgistics Health’s operating costs, expose Wellgistics Health to fraud or theft, subject Wellgistics Health to potential liability and potentially disrupt Wellgistics Health’s business operations.
  • Risks Related to Financial and Accounting Matters
  • Wellgistics Health and its subsidiaries have, and entities that Wellgistics Health may acquire could have, significant outstanding debt. The debt and associated payment obligations of Wellgistics Health and its current and future subsidiaries could significantly increase in the future if Wellgistics Health and its current or future subsidiaries incur additional debt and do not retire existing debt.
  • Wellgistics Health’s quarterly results may fluctuate significantly based on seasonality and other factors.
  • Wellgistics Health has a substantial amount of goodwill and other intangible assets which could, in the future, become impaired and result in material non-cash charges to Wellgistics Health’s results of operations. Wellgistics Health may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on its financial condition, results of operations, and stock price.
  • Acquisitions Wellgistics Health pursues in its industry and related industries could result in operating difficulties, dilution to Wellgistics Health’s stockholders and other consequences harmful to Wellgistics Health’s business.
  • Wellgistics Health may incur non-cash impairment charges in the future associated with its portfolio of intangible assets, including goodwill.
  • Wellgistics Health’s level of debt may negatively impact its liquidity, restrict its operations and ability to respond to business opportunities, and increase its vulnerability to adverse economic and industry conditions, especially given that Wellgistics Health’s bank debt contains a variable interest rate component based on its corporate credit ratings.
  • Wellgistics Health’s existing credit agreement and any other credit or similar agreements into which Wellgistics Health may enter in the future may restrict its operations, particularly Wellgistics Health’s ability to respond to changes or to take certain actions regarding its business.
  • Risks Related to Regulatory and Legal Considerations
  • Wellgistics Health’s business is subject to substantial government regulation.
  • Anti-Kickback Statutes
  • Physician Self- Referral (“Stark”) Laws
  • False Claims Act
  • State Licensure and Accreditation
  • Health Information Privacy and Security Standards
  • Changes in the healthcare industry and regulatory environments may adversely affect Wellgistics Health’s businesses.
  • Wellgistics Health will be exposed to risks related to litigation and other legal proceedings.
  • A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on Wellgistics Health’s reputation and profitability.
  • Wellgistics Health could be adversely affected by product liability, product recall, personal injury or other health and safety issues.
  • Wellgistics Health could be subject to adverse changes in tax laws, regulations and interpretations or challenges to Wellgistics Health’s tax positions.
  • Risks Related to Wellgistics Health’s Intellectual Property
  • Despite the actions Wellgistics Health will take to defend and protect its intellectual property, Wellgistics Health may not be able to adequately protect or enforce its intellectual property rights or prevent unauthorized parties from copying or reverse engineering its solutions. Wellgistics Health’s efforts to protect and enforce its intellectual property rights and prevent third parties from violating its rights may be costly.
  • Third-party claims that Wellgistics Health is infringing intellectual property, whether successful or not, could subject it to costly and time-consuming litigation or expensive licenses, and its business could be adversely affected.
  • Wellgistics Health’s intellectual property applications for registration may not issue or be registered, which may have a material adverse effect on Wellgistics Health’s ability to prevent others from commercially exploiting products similar to Wellgistics Health’s.
  • In addition to patented technology, Wellgistics Health will rely on its unpatented proprietary technology, trade secrets, designs, experiences, work flows, data, processes, software and know-how.
  • Wellgistics Health may be subject to damages resulting from claims that it or its current or former employees have wrongfully used or disclosed alleged trade secrets of its employees’ former employers. Wellgistics Health may be subject to damages if its current or former employees wrongfully use or disclose Wellgistics Health’s trade secrets.
  • Risks Related to Being a Public Company
  • Wellgistics Health incurs increased costs as a result of operating as a public company, and its management will devote substantial time to compliance with its public company responsibilities and corporate governance practices.
  • Wellgistics Health’s management team has limited experience managing a public company.
  • Wellgistics Health’s ability to be successful will depend upon the efforts of Wellgistics Health’s board of directors and key personnel and the loss of such persons could negatively impact the operations and profitability of Wellgistics Health’s business.
  • Risks Related to Ownership of Wellgistics Health’s Common Stock
  • Delaware State Law includes anti-takeover provisions.
  • Claims for indemnification by Wellgistics Health’s directors and officers may reduce Wellgistics Health’s available funds to satisfy successful third-party claims against Wellgistics Health and may reduce the amount of money available to Wellgistics Health.
  • If securities or industry analysts do not publish or cease publishing research or reports about Wellgistics Health, its business, or its market, or if they change their recommendations regarding Wellgistics Health’s securities adversely, the price and trading volume of Wellgistics Health’s securities could decline.
  • There can be no assurance that Wellgistics Health will be able to comply with the continued listing standards of Nasdaq.
  • Our common stock is publicly traded and may be subject to the penny stock rules which may make it more difficult to sell our common stock.
  • An active market for Wellgistics Health’s securities may not develop, which would adversely affect the liquidity and price of Wellgistics Health’s securities.
  • The market price of Wellgistics Health Common Stock may decline as a result of various market factors.
  • Future sales, or the perception of future sales, by Wellgistics Health or its stockholders in the public market could cause the market price for Wellgistics Health Common Stock to decline.
  • Wellgistics Health qualifies as an “emerging growth company” as well as a smaller reporting company within the meaning of the Securities Act, and if Wellgistics Health takes advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, this could make Wellgistics Health’s securities less attractive to investors and may make it more difficult to compare Wellgistics Health’s performance with other public companies.
  • Certain existing stockholders acquired our securities at a price below the current trading price of such securities and may experience a positive rate of return based on the current trading price.

Legal proceedings

We are not currently involved in any legal proceedings, except as described below. From time to time, we may become a party to various legal actions and complaints arising in the ordinary course of business. In addition to commitments and obligations in the ordinary course of business, we may be subject to various claims, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. It is possible that our cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

Dispute with Former Management

On October 10, 2025, the Company initiated litigation in the Circuit Court of the Thirteenth Judicial Circuit in and Hillsborough County, Florida against certain former officers and/or directors of the Company (collectively, the “Former Management Parties”). The complaint asserts claims including, among others, breach of the fiduciary duty of loyalty, breach of contract, tortious interference with a contract, tortious interference with business relationships, and other applicable claims, arising out of the Former Management Parties’ efforts to threaten harm the Company as leverage to force the retraction of a vote of the majority shareholders.

On December 10, 2025, Defendants filed a motion to compel arbitration of all claims in the suit. The Company does not agree that all the claims in the suit are subject to mandatory arbitration, and filed an opposition to that motion on December 22, 2025. A hearing is currently scheduled on the motion to compel arbitration for April 27, 2026.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39